Literature DB >> 14622118

Cleavage of recombinant proenkephalin and blockade mutants by prohormone convertases 1 and 2: an in vitro specificity study.

Juan R Peinado1, Hong Li, Karla Johanning, Iris Lindberg.   

Abstract

Proenkephalin (PE) derived-peptides are thought to be generated predominantly through endoproteolytic cleavage by prohormone convertases 1 and 2 (PC1 and PC2). In order to compare cleavage site preferences of these convertases, we studied the processing of recombinant wild-type rat PE and of two mutant PEs by recombinant purified mouse PC1 and PC2. Western blot analyses of timed digestions showed that both mouse PC1 and PC2 were able to produce a variety of large and intermediate sized-peptides from wild-type PE as well as from the precursors mutated at initial blockade sites. PC2 exhibited a broader specificity against PE than PC1, generating a much greater number of peptide products. Mass spectrometric identification of cleavage products showed that PC2 appeared to be the principal enzyme involved in the generation of smaller active opioids. Both enzymes were able to cleave various KR- and KK-containing sites, but PC2 was also able to cleave efficiently at an RR-V site and a KK-M site not cleaved by PC1, suggesting the exclusion of large aliphatic residues at the P1' position in PC1 cleavage. Alternative cleavage sites were readily chosen by convertases in blockade mutants, confirming in vivo results that cleavages do not follow an obligatory order. Furthermore, glycosylated PE was less efficiently processed by PC2, indicating that glycosylation may serve as a mechanism to hinder processing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622118     DOI: 10.1046/j.1471-4159.2003.02043.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives.

Authors:  Mirella Vivoli; Thomas R Caulfield; Karina Martínez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

2.  Substrate cleavage analysis of furin and related proprotein convertases. A comparative study.

Authors:  Albert G Remacle; Sergey A Shiryaev; Eok-Soo Oh; Piotr Cieplak; Anupama Srinivasan; Ge Wei; Robert C Liddington; Boris I Ratnikov; Amelie Parent; Roxane Desjardins; Robert Day; Jeffrey W Smith; Michal Lebl; Alex Y Strongin
Journal:  J Biol Chem       Date:  2008-05-27       Impact factor: 5.157

3.  Processing of proaugurin is required to suppress proliferation of tumor cell lines.

Authors:  Akihiko Ozawa; Adam N Lick; Iris Lindberg
Journal:  Mol Endocrinol       Date:  2011-03-24

4.  Modulation of prohormone convertase 1/3 properties using site-directed mutagenesis.

Authors:  Akihiko Ozawa; Juan R Peinado; Iris Lindberg
Journal:  Endocrinology       Date:  2010-07-07       Impact factor: 4.736

5.  Regulated proenkephalin expression in human skin and cultured skin cells.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Anna A Brozyna; Jackie Granese; Alexander Pisarchik; Andre Szczesniewski; Desmond J Tobin
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

6.  Distinct Dibasic Cleavage Specificities of Neuropeptide-Producing Cathepsin L and Cathepsin V Cysteine Proteases Compared to PC1/3 and PC2 Serine Proteases.

Authors:  Michael C Yoon; Janneca Ames; Charles Mosier; Zhenze Jiang; Sonia Podvin; Anthony J O'Donoghue; Vivian Hook
Journal:  ACS Chem Neurosci       Date:  2022-01-05       Impact factor: 5.780

7.  Synthetic small-molecule prohormone convertase 2 inhibitors.

Authors:  Dorota Kowalska; Jin Liu; Jon R Appel; Akihiko Ozawa; Adel Nefzi; Robert B Mackin; Richard A Houghten; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2008-12-12       Impact factor: 4.436

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.